Browsing: Homepage Slider

Untitled design(2)

Read time: 4:30 mins
In this column, Afshin Safavi differentiates between ‘assay qualification’ and ‘assay validation’ explaining current industry guidance, the translation of this guidance into the exploratory biomarker world, and how Bioagilytix (NC, USA) approaches these challenges.

ATE HRMS (1)_Feature

To address questions raised in our Quantitative HRMS Spotlight and to investigate how the field has progressed over the last two years, key figures from pharma, CROs, biotech and academia share with us their experiences and thoughts on HRMS, giving our members a 360° opinion series.


In this month long feature, we bring you a collection of content focusing on the ‘hot topic’ of immuno-oncology.


This entry is part 1 of 4 in the series Business of bioanalysis: season 2

In late 2017 Bioanalysis and Bioanalysis Zone organized a panel discussion comprising of experts from leading CROs and pharmaceutical companies to converse about the latest topics in bioanalysis.
In this series of three panel discussions, key opinion leaders from both industries returned to partake in an open dialogue talking through the latest challenges the industry is facing and what changes they would like to see happen in the coming future.